tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Judah Frommer, 126 are a BUY (72.83%), 45 are a HOLD (26.01%), 2 are a SELL (1.16%).
Analyst Judah Frommer, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 53.25% that have a potential upside of 29.95% achieved within 191 days.
Judah Frommer’s has documented 319 price targets and ratings displayed on 30 stocks. The coverage is on Consumer Defensive, Consumer Cyclical, Healthcare sectors.
Most recent stock forecast was given on FIVE, Five Below at 17-Jul-2024.
Analyst best performing recommendations are on SRPT (SAREPTA THERAPEUTICS).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 5/15/2023. The price target of $151 was fulfilled within 1 day with a profit of $6.19 (3.94%) receiving and performance score of 39.38.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$90
$19.1 (26.94%)
$150
25 days ago
5/6 (83.33%)
$24.61 (37.64%)
206
Buy
$120
$49.1 (69.25%)
$155
29 days ago
5/10 (50%)
$53.5 (80.45%)
659
Hold
$64
$-6.9 (-9.73%)
$120
1 months ago
3/9 (33.33%)
$-4.47 (-6.53%)
208
Buy
$68
$-2.9 (-4.09%)
$145
1 months ago
12/15 (80%)
$-0.47 (-0.69%)
80
Hold
$80
$9.1 (12.83%)
$130
1 months ago
9/11 (81.82%)
$11.53 (16.84%)
107
Which stock is Judah Frommer is most bullish on?
Which stock is Judah Frommer is most reserved on?
What Year was the first public recommendation made by Judah Frommer?
